-
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
11 Feb 2026 17:30 GMT
… metastatic non–small cell lung cancer (NSCLC), serious adverse … with neoadjuvant chemotherapy (carboplatin and paclitaxel followed by … .
Non-Small Cell Lung Cancer
KEYTRUDA and KEYTRUDA QLEX … nonsquamous non–small cell lung cancer (NSCLC), with no …
-
A Prognostic Nomogram Combining Radiologic Emphysema and Clinical Parameters in Small Cell Lung Cancer
27 Jan 2026 21:30 GMT
… lung cancer (SCLC) represents a distinct subtype of lung cancer characterized … 15% of all lung cancers worldwide, is closely … ), followed by etoposide plus carboplatin (n = 14), irinotecan … cell lung cancer; OS, overall survival; SCLC, small cell lung cancer; …
-
Roy Castle lung cancer charity slams decision to deny Scots patients life-saving drug on the NHS
21 Jan 2026 16:39 GMT
… used in combination with carboplatin and etoposide has been shown … small cell lung cancer (ES-SCLC) – the deadliest form of lung cancer, with … of the Roy Castle Lung Cancer Foundation (founded by the … TV entertainer, who died from lung cancer in 1992), said: …
-
SMC approves Rybrevant for lung cancer treatment
11 Dec 2025 17:24 GMT
… (amivantamab) in combination with carboplatin and pemetrexed for use within … cell lung cancer (NSCLC) with activating EGFR exon 20 insertion mutations.
Lung cancer is … which showed that amivantamab with carboplatin and pemetrexed increased median progression …
-
Rybrevant accepted in Scotland for lung cancer treatment
08 Dec 2025 15:30 GMT
… (amivantamab) in combination with carboplatin and pemetrexed for use within … cell lung cancer (NSCLC) with activating EGFR exon 20 insertion mutations.
Lung cancer is … which showed that amivantamab with carboplatin and pemetrexed increased median progression …
-
Scientists Disable Gene to Resensitize Lung Tumors to Chemotherapy
02 Dec 2025 14:08 GMT
… CRISPR) technology can make lung cancer cells responsive to chemotherapy … lung cancer (NSCLC) that represents 20% to 30% of all lung cancer … 47;Cas9 to engineer lung cancer cells carrying the R34G … chemotherapy drugs such as carboplatin and paclitaxel. In …
-
Man With Lung Cancer Shows Pseudoprogression, No Tumour
26 Nov 2025 08:17 GMT
… right lower lobe received neoadjuvant carboplatin, paclitaxel, and nivolumab therapy. … response to neoadjuvant therapy in lung cancer. The term describes an apparent … cycles of neoadjuvant chemoimmunotherapy with carboplatin, paclitaxel, and nivolumab.
A …
-
CRISPR breakthrough disables gene, reverses resistant lung cancer growth: Study
24 Nov 2025 11:13 GMT
… landscape for resistant lung tumors. Researchers at Christiana … NRF2 gene restores lung cancer cells’ sensitivity … lung cancer that accounts for 20-30% of lung cancer cases. Scientists engineered lung cancer … chemotherapy drugs like carboplatin and paclitaxel, …
-
Innovative CRISPR strategy resensitizes lung cancer to treatment
17 Nov 2025 18:25 GMT
… reverse chemotherapy resistance in lung cancer. The approach restores drug … Editing Institute
Potential beyond lung cancer
The study focused on … Cas9, the team engineered lung cancer cells with the R34G … chemotherapy drugs such as carboplatin and paclitaxel. In …
-
CRISPR unlocks a new way to defeat resistant lung cancer
17 Nov 2025 15:53 GMT
… CRISPR technology can make lung cancer cells responsive to chemotherapy … lung cancer (NSCLC) that represents 20% to 30% of all lung cancer … 47;Cas9 to engineer lung cancer cells carrying the R34G … chemotherapy drugs such as carboplatin and paclitaxel. In animal …
About
© 1995-2026